Research programme: CCR1 receptor antagonists - Ligand

Drug Profile

Research programme: CCR1 receptor antagonists - Ligand

Alternative Names: PS 031291; PS 375179

Latest Information Update: 11 Mar 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pharmacopeia Drug Discovery
  • Developer Ligand Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action CCR1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Cancer
  • Discontinued Multiple sclerosis; Rheumatoid arthritis

Most Recent Events

  • 11 Mar 2011 Ligand's CCR1 receptor antagonists research programme is still available for licensing. www.ligand.com
  • 09 Feb 2009 PS 031291 is available for out-licensing (http://www.pharmacopeia.com)
  • 23 Dec 2008 Pharmacopeia has been acquired by Ligand Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top